The Mansion House Accord, a landmark agreement designed to revitalise London's initial public offering (IPO) market, is facing scrutiny as the Alternative Investment Market (AIM) experiences a sharp decline in new listings. Critics argue that the accord, which brought together pension funds and regulators, has failed to address the specific challenges facing smaller companies.
Declining Listings on AIM
Data shows that the number of companies joining AIM has fallen to its lowest level in over a decade. In 2023, only 20 new companies listed on the junior market, compared to 45 in 2022 and a peak of 120 in 2006. This trend has raised concerns about the health of London's ecosystem for growth-stage businesses.
Pension Fund Investment Stalled
A key pillar of the Mansion House Accord was a commitment from major pension funds to allocate a greater share of their assets to unlisted and smaller listed companies. However, progress has been slow. While some funds have increased their exposure, many remain cautious due to liquidity concerns and regulatory constraints.
One fund manager noted, "The accord set high expectations, but the reality is that pension funds are still heavily weighted towards large-cap stocks. The infrastructure for investing in smaller companies needs further development."
Regulatory Hurdles Persist
Despite efforts to streamline listing rules, companies still face significant administrative burdens. The cost of compliance with AIM regulations, including the requirement for a nominated adviser, remains a barrier for many early-stage firms. Additionally, the UK's post-Brexit regulatory framework has created uncertainty for international investors.
Alternative Funding Sources Emerge
As AIM listings dwindle, smaller companies are turning to alternative funding sources. Private equity, venture capital, and crowdfunding platforms have become popular routes for raising capital. Some firms are also opting to list on other exchanges, such as the Nasdaq or Euronext, which offer more favourable conditions for tech and biotech companies.
"The Mansion House Accord was a step in the right direction, but it hasn't gone far enough," said a corporate finance adviser. "We need a more comprehensive strategy that addresses the entire funding lifecycle for small caps."
Government and Regulator Response
The UK government and the Financial Conduct Authority (FCA) have acknowledged the challenges. In response, they have proposed further reforms, including a review of the prospectus regime and measures to encourage retail investor participation. However, industry insiders argue that more decisive action is needed to restore confidence in AIM.
"The Mansion House Accord was never going to be a silver bullet," commented a market analyst. "But if it fails to deliver meaningful change, London risks losing its status as a leading hub for growth companies."
As the debate continues, all eyes will be on the next wave of IPOs and whether the accord can finally fulfil its promise.
